Does intensive glycemic control for type 2 diabetes mellitus have long-term benefits for cardiovascular disease risk?

Research output: Contribution to journalComment / DebateOtherpeer-review

1 Citation (Scopus)

Abstract

This Practice Point commentary discusses the findings of the 10-year follow-up of the United Kingdom Prospective Diabetes Study, which was a multicenter, randomized, controlled trial in which patients with newly diagnosed type 2 diabetes mellitus received conventional or intensive glycemic control. The follow-up study by Holman et al. suggests that intensive glycemic control can have long-lasting benefits in reducing the incidence not only of diabetes-related end points and microvascular complications (as shown in the original UKPDS study) but also of myocardial infarction and death from any cause. These benefits occurred despite the early loss of within-trial differences in HbA1c levels between the intensive and conventional treatment groups. The findings of Holman et al. support the notion of a sustained, legacy effect of intensive glycemic control, which was originally suggested in the Epidemiology of Diabetes Interventions and Complications study.

Original languageEnglish
Pages (from-to)138-139
Number of pages2
JournalNature Reviews Endocrinology
Volume5
Issue number3
DOIs
Publication statusPublished - Mar 2009
Externally publishedYes

Keywords

  • Diabetes
  • Intensive glycemic control
  • Macrovascular complications
  • Microvascular complications

Cite this

@article{7245119a1d454fb2a77a7c60cbc3604c,
title = "Does intensive glycemic control for type 2 diabetes mellitus have long-term benefits for cardiovascular disease risk?",
abstract = "This Practice Point commentary discusses the findings of the 10-year follow-up of the United Kingdom Prospective Diabetes Study, which was a multicenter, randomized, controlled trial in which patients with newly diagnosed type 2 diabetes mellitus received conventional or intensive glycemic control. The follow-up study by Holman et al. suggests that intensive glycemic control can have long-lasting benefits in reducing the incidence not only of diabetes-related end points and microvascular complications (as shown in the original UKPDS study) but also of myocardial infarction and death from any cause. These benefits occurred despite the early loss of within-trial differences in HbA1c levels between the intensive and conventional treatment groups. The findings of Holman et al. support the notion of a sustained, legacy effect of intensive glycemic control, which was originally suggested in the Epidemiology of Diabetes Interventions and Complications study.",
keywords = "Diabetes, Intensive glycemic control, Macrovascular complications, Microvascular complications",
author = "Georgia Soldatos and Cooper, {Mark E.}",
year = "2009",
month = "3",
doi = "10.1038/ncpendmet1076",
language = "English",
volume = "5",
pages = "138--139",
journal = "Nature Reviews Endocrinology",
issn = "1759-5029",
publisher = "Nature Publishing Group",
number = "3",

}

Does intensive glycemic control for type 2 diabetes mellitus have long-term benefits for cardiovascular disease risk? / Soldatos, Georgia; Cooper, Mark E.

In: Nature Reviews Endocrinology, Vol. 5, No. 3, 03.2009, p. 138-139.

Research output: Contribution to journalComment / DebateOtherpeer-review

TY - JOUR

T1 - Does intensive glycemic control for type 2 diabetes mellitus have long-term benefits for cardiovascular disease risk?

AU - Soldatos, Georgia

AU - Cooper, Mark E.

PY - 2009/3

Y1 - 2009/3

N2 - This Practice Point commentary discusses the findings of the 10-year follow-up of the United Kingdom Prospective Diabetes Study, which was a multicenter, randomized, controlled trial in which patients with newly diagnosed type 2 diabetes mellitus received conventional or intensive glycemic control. The follow-up study by Holman et al. suggests that intensive glycemic control can have long-lasting benefits in reducing the incidence not only of diabetes-related end points and microvascular complications (as shown in the original UKPDS study) but also of myocardial infarction and death from any cause. These benefits occurred despite the early loss of within-trial differences in HbA1c levels between the intensive and conventional treatment groups. The findings of Holman et al. support the notion of a sustained, legacy effect of intensive glycemic control, which was originally suggested in the Epidemiology of Diabetes Interventions and Complications study.

AB - This Practice Point commentary discusses the findings of the 10-year follow-up of the United Kingdom Prospective Diabetes Study, which was a multicenter, randomized, controlled trial in which patients with newly diagnosed type 2 diabetes mellitus received conventional or intensive glycemic control. The follow-up study by Holman et al. suggests that intensive glycemic control can have long-lasting benefits in reducing the incidence not only of diabetes-related end points and microvascular complications (as shown in the original UKPDS study) but also of myocardial infarction and death from any cause. These benefits occurred despite the early loss of within-trial differences in HbA1c levels between the intensive and conventional treatment groups. The findings of Holman et al. support the notion of a sustained, legacy effect of intensive glycemic control, which was originally suggested in the Epidemiology of Diabetes Interventions and Complications study.

KW - Diabetes

KW - Intensive glycemic control

KW - Macrovascular complications

KW - Microvascular complications

UR - http://www.scopus.com/inward/record.url?scp=60749117415&partnerID=8YFLogxK

U2 - 10.1038/ncpendmet1076

DO - 10.1038/ncpendmet1076

M3 - Comment / Debate

VL - 5

SP - 138

EP - 139

JO - Nature Reviews Endocrinology

JF - Nature Reviews Endocrinology

SN - 1759-5029

IS - 3

ER -